It’s been just over a year since President Joe Biden announced plans to reignite the Cancer Moonshot initiative, established in 2016 during his stint as vice president. With a target of halving the cancer death rate within the next 25 years, it seemed a Herculean undertaking.
But few areas in healthcare can unite stakeholders across industry, political leanings, and social status, quite like cancer. Evoking the collaborative spirit inspired by President John F. Kennedy’s moonshot vision, over the past year the Cancer Moonshot has made remarkable progress, paralleling the unwavering dedication, cutting-edge technologies, and scientific curiosity required to boldly venture into uncharted territories, seeking breakthroughs that will transform the lives of patients.
In this issue, we take a look back at the progress made under the Cancer Moonshot programme, and shine a spotlight on CancerX, which aims to bring diverse stakeholders together to leverage digital technology to tackle the biggest challenges in cancer.
Also, find out how Daiichi Sankyo and AstraZeneca are working together to reduce barriers to cancer care in Europe, explore the challenge of cancer drug resistance with Ribonexus, review the burgeoning European oncology CAR-T market access space with Research Partnership, and hear from Phesi’s Dr Gen Li as he discusses unlocking the power of data in oncology.
Plus, we hit the floor at ASCO to find out how experts view the future of artificial intelligence, and MSD examines the future oncology workforce.
For all this, as well as the latest news, trends, and events, read on.
Eloise McLennan – editor, Deep Dive
For the best page-viewing experience, make sure you have your browser at full-screen size. Use the left/right arrow buttons to scroll through the pages or click on the menu icon bottom centre to navigate. You can also share the articles on social media by clicking the icon bottom left at the base of the main navigation or at the end of each article.